APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroprotective Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroprotective Drugs Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchNeuroprotective Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroprotective Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Neuroprotective Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroprotective Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroprotective Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neuroprotective Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroprotective Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroprotective Drugs market include Teva Pharmaceutical Industries Ltd, Novartis, Merck KGaA, Biogen, AstraZeneca, NeuroVive Pharmaceutical, Neuren Pharmaceuticals, Genervon Biopharmaceuticals and Ceregene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroprotective Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroprotective Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroprotective Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroprotective Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroprotective Drugs Segment by Company

Teva Pharmaceutical Industries Ltd

Novartis

Merck KGaA

Biogen

AstraZeneca

NeuroVive Pharmaceutical

Neuren Pharmaceuticals

Genervon Biopharmaceuticals

Ceregene

Bionure

BHR Pharma

Allon therapeutics

Neuroprotective Drugs Segment by Type

Cholinesterase inhibitors

Anti-inflammatory

Others

Neuroprotective Drugs Segment by Application

Alzheimer's disease

Parkinson's disease

Others

Neuroprotective Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuroprotective Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuroprotective Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroprotective Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroprotective Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroprotective Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroprotective Drugs industry.

Chapter 3: Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuroprotective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuroprotective Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroprotective Drugs Industry Trends Table 2. Neuroprotective Drugs Industry Drivers Table 3. Neuroprotective Drugs Industry Opportunities and Challenges Table 4. Neuroprotective Drugs Industry Restraints Table 5. Global Neuroprotective Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroprotective Drugs Revenue Share by Company (2021-2026) Table 7. Global Neuroprotective Drugs Sales Volume by Company (tons) & (2021-2026) Table 8. Global Neuroprotective Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Neuroprotective Drugs Average Price (US$/kg) of Company (2021-2026) Table 10. Global Neuroprotective Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuroprotective Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Neuroprotective Drugs Company, Product Type & Application Table 13. Global Neuroprotective Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroprotective Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cholinesterase inhibitors Table 18. Significant Companies of Anti-inflammatory Table 19. Significant Companies of Others Table 20. Global Neuroprotective Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (tons) Table 21. Global Neuroprotective Drugs Sales Volume by Type (2021-2026) & (tons) Table 22. Global Neuroprotective Drugs Sales Volume by Type (2027-2032) & (tons) Table 23. Global Neuroprotective Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Neuroprotective Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Neuroprotective Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neuroprotective Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Neuroprotective Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Neuroprotective Drugs Sales Value Share by Type (2021-2026) Table 29. Global Neuroprotective Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Alzheimer's disease Table 31. Significant Companies of Parkinson's disease Table 32. Significant Companies of Others Table 33. Global Neuroprotective Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (tons) Table 34. Global Neuroprotective Drugs Sales Volume by Application (2021-2026) & (tons) Table 35. Global Neuroprotective Drugs Sales Volume by Application (2027-2032) & (tons) Table 36. Global Neuroprotective Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Neuroprotective Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Neuroprotective Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Neuroprotective Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Neuroprotective Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Neuroprotective Drugs Sales Value Share by Application (2021-2026) Table 42. Global Neuroprotective Drugs Sales Value Share by Application (2027-2032) Table 43. Global Neuroprotective Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 44. Global Neuroprotective Drugs Sales by Region (2021-2026) & (tons) Table 45. Global Neuroprotective Drugs Sales Market Share by Region (2021-2026) Table 46. Global Neuroprotective Drugs Sales by Region (2027-2032) & (tons) Table 47. Global Neuroprotective Drugs Sales Market Share by Region (2027-2032) Table 48. Global Neuroprotective Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Neuroprotective Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Neuroprotective Drugs Sales Value Share by Region (2021-2026) Table 51. Global Neuroprotective Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Neuroprotective Drugs Sales Value Share by Region (2027-2032) Table 53. Global Neuroprotective Drugs Market Average Price (US$/kg) by Region (2021-2026) Table 54. Global Neuroprotective Drugs Market Average Price (US$/kg) by Region (2027-2032) Table 55. Global Neuroprotective Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Table 56. Global Neuroprotective Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 58. Global Neuroprotective Drugs Sales Market Share by Country (2021-2026) Table 59. Global Neuroprotective Drugs Sales by Country (2027-2032) & (tons) Table 60. Global Neuroprotective Drugs Sales Market Share by Country (2027-2032) Table 61. Global Neuroprotective Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Neuroprotective Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Neuroprotective Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Neuroprotective Drugs Sales Value Market Share by Country (2027-2032) Table 65. Teva Pharmaceutical Industries Ltd Company Information Table 66. Teva Pharmaceutical Industries Ltd Business Overview Table 67. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 68. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolio Table 69. Teva Pharmaceutical Industries Ltd Recent Development Table 70. Novartis Company Information Table 71. Novartis Business Overview Table 72. Novartis Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 73. Novartis Neuroprotective Drugs Product Portfolio Table 74. Novartis Recent Development Table 75. Merck KGaA Company Information Table 76. Merck KGaA Business Overview Table 77. Merck KGaA Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 78. Merck KGaA Neuroprotective Drugs Product Portfolio Table 79. Merck KGaA Recent Development Table 80. Biogen Company Information Table 81. Biogen Business Overview Table 82. Biogen Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 83. Biogen Neuroprotective Drugs Product Portfolio Table 84. Biogen Recent Development Table 85. AstraZeneca Company Information Table 86. AstraZeneca Business Overview Table 87. AstraZeneca Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 88. AstraZeneca Neuroprotective Drugs Product Portfolio Table 89. AstraZeneca Recent Development Table 90. NeuroVive Pharmaceutical Company Information Table 91. NeuroVive Pharmaceutical Business Overview Table 92. NeuroVive Pharmaceutical Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 93. NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolio Table 94. NeuroVive Pharmaceutical Recent Development Table 95. Neuren Pharmaceuticals Company Information Table 96. Neuren Pharmaceuticals Business Overview Table 97. Neuren Pharmaceuticals Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 98. Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolio Table 99. Neuren Pharmaceuticals Recent Development Table 100. Genervon Biopharmaceuticals Company Information Table 101. Genervon Biopharmaceuticals Business Overview Table 102. Genervon Biopharmaceuticals Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 103. Genervon Biopharmaceuticals Neuroprotective Drugs Product Portfolio Table 104. Genervon Biopharmaceuticals Recent Development Table 105. Ceregene Company Information Table 106. Ceregene Business Overview Table 107. Ceregene Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 108. Ceregene Neuroprotective Drugs Product Portfolio Table 109. Ceregene Recent Development Table 110. Bionure Company Information Table 111. Bionure Business Overview Table 112. Bionure Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 113. Bionure Neuroprotective Drugs Product Portfolio Table 114. Bionure Recent Development Table 115. BHR Pharma Company Information Table 116. BHR Pharma Business Overview Table 117. BHR Pharma Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 118. BHR Pharma Neuroprotective Drugs Product Portfolio Table 119. BHR Pharma Recent Development Table 120. Allon therapeutics Company Information Table 121. Allon therapeutics Business Overview Table 122. Allon therapeutics Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 123. Allon therapeutics Neuroprotective Drugs Product Portfolio Table 124. Allon therapeutics Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Neuroprotective Drugs Distributors List Table 128. Neuroprotective Drugs Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Neuroprotective Drugs Product Image Figure 2. Global Neuroprotective Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroprotective Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuroprotective Drugs Sales (2021-2032) & (tons) Figure 5. Global Neuroprotective Drugs Sales Average Price (US$/kg) & (2021-2032) Figure 6. Global Neuroprotective Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cholinesterase inhibitors Image Figure 10. Anti-inflammatory Image Figure 11. Others Image Figure 12. Global Neuroprotective Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (tons) Figure 13. Global Neuroprotective Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Neuroprotective Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Neuroprotective Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Neuroprotective Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Neuroprotective Drugs Sales Value Share by Type (2021-2032) Figure 18. Alzheimer's disease Image Figure 19. Parkinson's disease Image Figure 20. Others Image Figure 21. Global Neuroprotective Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (tons) Figure 22. Global Neuroprotective Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Neuroprotective Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Neuroprotective Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Neuroprotective Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Neuroprotective Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Neuroprotective Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 28. Global Neuroprotective Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Neuroprotective Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Neuroprotective Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Neuroprotective Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Neuroprotective Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Neuroprotective Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Neuroprotective Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Neuroprotective Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Neuroprotective Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Neuroprotective Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Neuroprotective Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Neuroprotective Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Neuroprotective Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Neuroprotective Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Neuroprotective Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Neuroprotective Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Cholinesterase inhibitors
  • Anti-inflammatory
  • Others
Applications
  • Alzheimer's disease
  • Parkinson's disease
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Novartis
  • Merck KGaA
  • Biogen
  • AstraZeneca
  • NeuroVive Pharmaceutical
  • Neuren Pharmaceuticals
  • Genervon Biopharmaceuticals
  • Ceregene
  • Bionure
  • BHR Pharma
  • Allon therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroprotective Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Neuroprotective Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Neuroprotective Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuroprotective Drugs Market Dynamics
  1. 2.1 Neuroprotective Drugs Industry Trends
  2. 2.2 Neuroprotective Drugs Industry Drivers
  3. 2.3 Neuroprotective Drugs Industry Opportunities and Challenges
  4. 2.4 Neuroprotective Drugs Industry Restraints
3 Neuroprotective Drugs Market by Company
  1. 3.1 Global Neuroprotective Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Neuroprotective Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Neuroprotective Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuroprotective Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Neuroprotective Drugs Company Ranking (2024-2026)
  6. 3.6 Global Neuroprotective Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuroprotective Drugs Company Product Type and Application
  8. 3.8 Global Neuroprotective Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuroprotective Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuroprotective Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuroprotective Drugs Market by Type
  1. 4.1 Neuroprotective Drugs Type Introduction
  2. 4.1.1 Cholinesterase inhibitors
  3. 4.1.2 Anti-inflammatory
  4. 4.1.3 Others
  5. 4.2 Global Neuroprotective Drugs Sales Volume by Type
  6. 4.2.1 Global Neuroprotective Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuroprotective Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Neuroprotective Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Neuroprotective Drugs Sales Value by Type
  10. 4.3.1 Global Neuroprotective Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neuroprotective Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Neuroprotective Drugs Sales Value Share by Type (2021-2032)
5 Neuroprotective Drugs Market by Application
  1. 5.1 Neuroprotective Drugs Application Introduction
  2. 5.1.1 Alzheimer's disease
  3. 5.1.2 Parkinson's disease
  4. 5.1.3 Others
  5. 5.2 Global Neuroprotective Drugs Sales Volume by Application
  6. 5.2.1 Global Neuroprotective Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroprotective Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Neuroprotective Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Neuroprotective Drugs Sales Value by Application
  10. 5.3.1 Global Neuroprotective Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuroprotective Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Neuroprotective Drugs Sales Value Share by Application (2021-2032)
6 Neuroprotective Drugs Regional Sales and Value Analysis
  1. 6.1 Global Neuroprotective Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroprotective Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroprotective Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Neuroprotective Drugs Sales by Region (2027-2032)
  5. 6.3 Global Neuroprotective Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuroprotective Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuroprotective Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuroprotective Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Neuroprotective Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuroprotective Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Neuroprotective Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuroprotective Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Neuroprotective Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuroprotective Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuroprotective Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuroprotective Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Neuroprotective Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuroprotective Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuroprotective Drugs Sales Value Share by Country, 2025 VS 2032
7 Neuroprotective Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Neuroprotective Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroprotective Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuroprotective Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Neuroprotective Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Neuroprotective Drugs Sales by Country (2027-2032)
  6. 7.4 Global Neuroprotective Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuroprotective Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuroprotective Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuroprotective Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuroprotective Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuroprotective Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd
  2. 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Neuroprotective Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck KGaA
  14. 8.3.1 Merck KGaA Company Information
  15. 8.3.2 Merck KGaA Business Overview
  16. 8.3.3 Merck KGaA Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck KGaA Neuroprotective Drugs Product Portfolio
  18. 8.3.5 Merck KGaA Recent Developments
  19. 8.4 Biogen
  20. 8.4.1 Biogen Company Information
  21. 8.4.2 Biogen Business Overview
  22. 8.4.3 Biogen Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Biogen Neuroprotective Drugs Product Portfolio
  24. 8.4.5 Biogen Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Neuroprotective Drugs Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 NeuroVive Pharmaceutical
  32. 8.6.1 NeuroVive Pharmaceutical Company Information
  33. 8.6.2 NeuroVive Pharmaceutical Business Overview
  34. 8.6.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolio
  36. 8.6.5 NeuroVive Pharmaceutical Recent Developments
  37. 8.7 Neuren Pharmaceuticals
  38. 8.7.1 Neuren Pharmaceuticals Company Information
  39. 8.7.2 Neuren Pharmaceuticals Business Overview
  40. 8.7.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolio
  42. 8.7.5 Neuren Pharmaceuticals Recent Developments
  43. 8.8 Genervon Biopharmaceuticals
  44. 8.8.1 Genervon Biopharmaceuticals Company Information
  45. 8.8.2 Genervon Biopharmaceuticals Business Overview
  46. 8.8.3 Genervon Biopharmaceuticals Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Genervon Biopharmaceuticals Neuroprotective Drugs Product Portfolio
  48. 8.8.5 Genervon Biopharmaceuticals Recent Developments
  49. 8.9 Ceregene
  50. 8.9.1 Ceregene Company Information
  51. 8.9.2 Ceregene Business Overview
  52. 8.9.3 Ceregene Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ceregene Neuroprotective Drugs Product Portfolio
  54. 8.9.5 Ceregene Recent Developments
  55. 8.10 Bionure
  56. 8.10.1 Bionure Company Information
  57. 8.10.2 Bionure Business Overview
  58. 8.10.3 Bionure Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bionure Neuroprotective Drugs Product Portfolio
  60. 8.10.5 Bionure Recent Developments
  61. 8.11 BHR Pharma
  62. 8.11.1 BHR Pharma Company Information
  63. 8.11.2 BHR Pharma Business Overview
  64. 8.11.3 BHR Pharma Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 BHR Pharma Neuroprotective Drugs Product Portfolio
  66. 8.11.5 BHR Pharma Recent Developments
  67. 8.12 Allon therapeutics
  68. 8.12.1 Allon therapeutics Company Information
  69. 8.12.2 Allon therapeutics Business Overview
  70. 8.12.3 Allon therapeutics Neuroprotective Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Allon therapeutics Neuroprotective Drugs Product Portfolio
  72. 8.12.5 Allon therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroprotective Drugs Value Chain Analysis
  2. 9.1.1 Neuroprotective Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroprotective Drugs Sales Mode & Process
  6. 9.2 Neuroprotective Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroprotective Drugs Distributors
  9. 9.2.3 Neuroprotective Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst